Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma.

GLP-1R agonist use was associated with a statistically significant hazard reduction for a new diagnosis of glaucoma. Our findings support further investigations into the use of GLP-1R agonists in glaucoma prevention.